Hesham HAMED, pharmacist by training, holding an MSc and PhD in pharmacology with a focus on drug discovery. He is a senior scientist/lecturer at the University of Geneva, and currently serves as the CSO and Co-CEO of Adoram Therapeutics, a spin-off from the University of Geneva that focuses on the development and commercialization of allosteric modulators for GPCRs.
With 20 years of experience in life sciences and pharmacology, Dr. Hamed’s work has centred on studying the pathophysiology of diseases, validating therapeutic targets, and developing small molecules therapies aimed at tackling unmet medical needs. Dr. Hamed’s research has contributed to advancing two small molecules into clinical trials (Phase Ib and III), through academic collaborations and partnerships with the pharmaceutical and biotech industries. He has also provided consulting services for Novartis and Skyhawk Therapeutics.
My career directive has always been to address unmet medical needs. With Revadix, I saw how this innovation can change lives of millions of patients living or in risk of atrial fibrillation. This is only the start, while many other indications remain in our focus for future inidcations.
